Realta Fusion and Commonwealth Fusion Systems (CFS) have formed a strategic partnership for the design and manufacturing of high-temperature superconducting (HTS) magnets that Realta will use to accelerate the commercialization…
SHINE Technologies has entered a supply agreement with C-Ray Therapeutics, a global radiopharmaceutical CRDMO, the company announced recently. According to a release, C-Ray will supply SHINE’s n.c.a. Lu-177 to Chinese…
BrainXell is launching its human induced pluripotent stem cell (iPSC)-derived sensory neurons, the company announced recently. According to a release, the iPSC-derived sensory neurons are a scalable human cellular platform…
SHINE Technologies has raised $240 million in equity funding, the company announced recently. The round was led by NantWorks with additional participation from Fidelity Management & Research Company, Sumitomo Corporation of…
Elephas Biosciences Corporation is partnering with the University of Louisville on a new research opportunity that will evaluate the impact of a combination therapy of surgical intervention and immunotherapy in…
NorthStar Medical Radioisotopes has entered into a strategic supply agreement with BIOEMTECH, a developer of high-resolution PET and SPECT imaging systems for preclinical and translational research, the company announced today….
Promega is launching the TarSeer BRETSA Target Engagement System, a live-cell, target engagement platform that could close a long-standing gap between biochemical and cellular assays for understudied or difficult-to-interrogate proteins,…
Forward BIOLABS, in partnership with BioForward Madison, announced today the first round of awardees of the Innovation to Commercialization Pipeline (ICP) program. The awardees from the Madison area include Immuto…
Immuto Scientific and the University of Wisconsin announced recently a collaborative agreement to identify disease-specific novel therapeutic targets in colorectal cancer using Immuto’s proprietary structural surfaceomics platform. “Our work with…
FAR Biotech, a computational drug discovery company using proprietary quantum modeling and deep learning AI to tackle high-impact diseases with significant unmet medical need, announced recently that it has moved…
